Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including Cubist, MorphoSys, AstraZeneca and Takeda.

Latest News

Dec 15, 2014

Heptares’ Extends Global Patent Protection For GPCR-Focused Drug Discovery Platform With Grant Of Core Patents In The United States

Nov 20, 2014

Heptares Orphan Disease Programme Awarded Grant From The UK Biomedical Catalyst


Jan 10-11, 2015
East/West CEO Conference
San Francisco, USA
Presenting: Malcolm Weir, Dan Grau

Jan 12-15, 2015
JPMorgan Healthcare Conference
San Francisco, CA, USA
Attending: Malcolm Weir, Dan Grau

© 2012-2014 Heptares Therapeutics